- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00941642
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
June 9, 2010 updated by: Huntington Medical Research Institutes
Lovaza is the only fish oil supplement approved by the FDA.
It is available by prescription for the treatment of hypertriglyceridemia (> 500 mg/dl).
The primary mechanism appears to be a reduction in hepatic production of triglycerides.
Also decreases the hepatic production of very low density lipoprotein (VLDL).
There also may be antioxidant properties as well.
The thought behind using Lovaza as a treatment for non-alcoholic fatty liver disease (NAFLD) is two fold.
It would help in the decrease production of triglycerides by the liver and have antioxidant properties decreasing the production of free radicals in the liver.
In doing so, steatohepatitis, fibrosis, and perhaps cirrhosis and liver cancer would be prevented.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Pasadena, California, United States, 91105
- Recruiting
- HMRI - Liver Center
-
Contact:
- Roberta A Fitzgerald, RN
- Phone Number: 626-397-5825
- Email: robertaf@hmri.org
-
Principal Investigator:
- Edward A Mena, MD
-
Sub-Investigator:
- Myron J Tong, PhD, MD.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Over the age of 18
- Abnormal liver enzymes >40 IU/L. Definition of normal is ALT 19 for a woman and 30 for a man.
- Patients must meet ATP III criteria for metabolic syndrome: Central obesity as measured by waist circumference. Men - greater than or equal to 40 inches. Women - greater than or equal to 35 inches.
- Blood HDL cholesterol. Men - less than 40 mg/dL. Women - less than 50 mg /dL.
- Blood pressure greater than or equal to 130/85.
- Fasting glucose greater than or equal to 100 mg/dL but less than 126mg/dL on 2 separate occasions.
- Fasting blood triglycerides greater than or equal to 150 mg/dL.
- Hepatitis B and C negative
- Autoimmune Hepatitis, Wilson's Disease, Hemochromatosis negative, etc.
- NASH or NAFLD on biopsy of any degree:
Exclusion Criteria:
- Below the age of 18.
- Other Causes of Liver inflammation.
- Daily alcohol consumption in excess of 20 grams / day for men and 10 grams / day for women. If participant unable to quantify his/her alcohol intake, they should be excluded.
- Taking a prescribed medication know to cause fatty liver disease 6 months prior to enrollment. Also, subjects with secondary causes of fatty liver disease (ie. Gastric bypass) should be excluded from the study.
- Cirrhosis.
- Subjects on oral insulin-sensitizing agents and other drugs currently being used in the treatment of NAFLD. Such agents include fibrates, Vitamin E, S-adenosyl-methionine, betaine, N-acetylcysteine, and milk thistle extracts.
- Diabetes (fasting sugar above 126mg/dl).
- Pregnancy or lactation. Women of child bearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test prior to treatment and be practicing an acceptable form of barrier contraception for the duration of the study.
- Any serious or chronic disease that in the opinion of the Principal Investigator (PI), may affect the assessment of safety or efficacy parameters. This includes but is not limited to, patients with malignancy, other than Basal Cell Carcinomas.
- Patients who, in the opinion of the site PI, are not suitable candidates for enrollment or would not comply with the requirements of the study.
- Patients who have had a liver transplant.
- Any allergy to fish.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lovaza
Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA.
The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
|
Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza.
Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
|
Placebo Comparator: Placebo
Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell.
Subjects will take 4g daily for a minimum of 48 weeks.
|
Approximately 50% of study subjects will be randomized to the placebo arm of this study.
Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if Lovaza improves fibrosis and the NASH activity index.
Time Frame: 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if Lovaza improves AST/ALT level and improves steatosis on biopsy.
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Edward A Mena, MD, Huntington Medical Research Institutes - Liver Center
- Study Director: Myron J Tong, PhD, MD., Huntington Medical Research Institutes - Liver Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Anticipated)
September 1, 2012
Study Completion (Anticipated)
September 1, 2012
Study Registration Dates
First Submitted
July 15, 2009
First Submitted That Met QC Criteria
July 16, 2009
First Posted (Estimate)
July 17, 2009
Study Record Updates
Last Update Posted (Estimate)
June 10, 2010
Last Update Submitted That Met QC Criteria
June 9, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOVAZA - NAFLD
- IND # 105,085.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on Lovaza
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Canada
-
University of VirginiaReliant PharmaceuticalsWithdrawn
-
University of MichiganGlaxoSmithKlineTerminated
-
University of TennesseeUnknownParenteral Nutrition Associated Liver DiseaseUnited States
-
St. Luke's-Roosevelt Hospital CenterGlaxoSmithKlineNo longer available
-
University of UtahGlaxoSmithKlineWithdrawnEffects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in HypertriglyceridemiaHypertriglyceridemiaUnited States
-
University of Illinois at ChicagoTerminatedNonalcoholic Steatohepatitis (NASH) | Hepatic SteatosisUnited States
-
Milton S. Hershey Medical CenterWithdrawn
-
Brigham and Women's HospitalGlaxoSmithKlineUnknown
-
United States Department of DefenseGlaxoSmithKlineUnknownDepression | Mood Disorders | Combat Disorders | Stress DisordersIraq